GlassScriptPhysician profile
Hannah Evans Ray
NPI 1366171514
$3,295.14
in general payments reported to CMS, 2019-2025
22 companies · $1,468 in 2025
The $1,468 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $149 · 2023: $608 · 2024: $1,070 · 2025: $1,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,962 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,962.35 |
| Education | $183.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $486.02 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $351.89 | 2023-2025 | Ilumya |
| Abbvie INC. | $337.54 | 2022-2025 | |
| Galderma Laboratories, L.P. | $298.34 | 2025 | Nemluvio |
| Leo Pharma INC. | $291.88 | 2023-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $261.96 | 2023-2024 | Siliq, Targretin, Duobrii |
| E.R. Squibb & Sons, L.L.C. | $199.07 | 2023-2025 | Sotyktu |
| Amgen INC. | $180.11 | 2024-2025 | Otezla, Otezla |
| Genzyme Corporation | $167.35 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $158.68 | 2024-2025 | Nuzyra |
| Lilly USA, LLC | $155.00 | 2023 | Olumiant, Taltz |
| Ucb, INC. | $115.73 | 2024-2025 | Bimzelx |
| Convatec INC. | $69.18 | 2025 | |
| Verrica Pharmaceuticals INC. | $39.32 | 2023-2024 | Ycanth |
| Genentech USA, INC. | $34.32 | 2025 | Xolair |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $28.84 | 2024 | Vtama |
| Janssen Biotech, INC. | $26.96 | 2025 | Tremfya |
| Incyte Corporation | $19.83 | 2025 | Opzelura |
| Organon LLC | $19.51 | 2025 | Vtama |
| Botanix Sb INC | $18.69 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $18.46 | 2025 | |
| Pfizer INC. | $16.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.